Indications for progression to anti-TNFα therapy
| Age | M/F | Reason for stopping AZP/allopurinol |
|---|---|---|
| 59 | M | Intolerant of allopurinol taste |
| 70 | F | Nausea and vomiting |
| 33 | F | Disease progression |
| 23 | F | Disease progression |
| 27 | F | Disease progression |
| 34 | F | Pregnancy |
| 36 | M | Loss of appetite |
| 66 | F | Nausea and vomiting |
| 85 | M | Disease progression |
| 35 | F | Disease progression |
| 60 | M | Disease progression |
| 28 | F | Weight gain* |
*Patient reported weight gain with LDTA and for this reason ceased LDTA and required escalation to anti-TNFα.
AZP, azathioprine; LDTA, low dose thiopurine and allopurinol.